Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated)

含有 Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) 的品牌、食物注意事项以及最重要的药物相互作用。

品牌

未找到该活性成分的已注册品牌。

食物注意事项

该活性成分暂无已收录的食物注意事项。

最重要的相互作用

前 10 项，共 50 项

Erenumab中等
当 Erenumab 与 Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) 联合使用时，发生不良反应的风险或严重程度可能增加。
专业视图
The risk or severity of adverse effects can be increased when Erenumab is combined with Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated).
Theophylline中等
当 Theophylline 与 Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) 联合使用时，Theophylline 的血药浓度可能升高。
专业视图
The serum concentration of Theophylline can be increased when it is combined with Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated).
2-Methoxyethanol轻微
当 Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) 与 2-Methoxyethanol 联合使用时，Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) 的治疗效果可能减弱。
专业视图
The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with 2-Methoxyethanol.
9-(N-methyl-L-isoleucine)-cyclosporin A轻微
当 Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) 与 9-(N-methyl-L-isoleucine)-cyclosporin A 联合使用时，Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) 的治疗效果可能减弱。
专业视图
The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with 9-(N-methyl-L-isoleucine)-cyclosporin A.
Abatacept轻微
当 Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) 与 Abatacept 联合使用时，Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) 的治疗效果可能减弱。
专业视图
The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Abatacept.
Abetimus轻微
当 Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) 与 Abetimus 联合使用时，Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) 的治疗效果可能减弱。
专业视图
The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Abetimus.
Acteoside轻微
当 Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) 与 Acteoside 联合使用时，Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) 的治疗效果可能减弱。
专业视图
The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Acteoside.
Adalimumab轻微
当 Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) 与 Adalimumab 联合使用时，Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) 的治疗效果可能减弱。
专业视图
The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Adalimumab.
Afelimomab轻微
当 Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) 与 Afelimomab 联合使用时，Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) 的治疗效果可能减弱。
专业视图
The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Afelimomab.
Aldesleukin轻微
当 Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) 与 Aldesleukin 联合使用时，Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) 的治疗效果可能减弱。
专业视图
The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Aldesleukin.